Is It Time To Revisit Agilent Technologies (A) After Recent Share Price Weakness

Lonza NewsLonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma Post

Eli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN

Thermo FisherThe Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why - Yahoo Finance

Bio-Gene Technology LtdBio-Gene lifts placement size with additional shares and options - TipRanks

10x Genomics BlogThis $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - AOL.com

Eli LillyGilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits

PfizerPfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord Pharma

Endpoints NewsOtsuka touts new IgAN evidence as it seeks full approval for Voyxact

AgilentA Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus - simplywall.st

Boston ScientificBoston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs - MassDevice

Charles RiverCharles River Laboratories stock (US1591881009): Insider grant and fresh fund buying keep focus on C - AD HOC NEWS

Endpoints NewsActing FDA chief isn't interested in permanent role